The FDA's stance on compounding BPC-157 is trending due to a recent advisory panel vote that narrowly supported allowing the compounding of unapproved peptides, including BPC-157. This decision could pave the way for clearer regulations and wider accessibility of these substances.
Get the full breakdown — why it matters, background context, and what comes next.
Read Full Analysis